

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)

ANNOUNCEMENT PROPOSED CHANGE OF AUDITORS

This announcement is made by Sinopharm Group Co. Ltd. (the “**Company**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The term of service of Ernst & Young, the current international auditor of the Company, and Ernst & Young Hua Ming LLP, the current domestic auditor of the Company (hereinafter collectively referred to as “**Ernst & Young**”) will expire on the date of 2022 annual general meeting (the “**2022 AGM**”) to be convened on Thursday, 15 June 2023. Pursuant to the relevant regulations issued by the Ministry of Finance of the People's Republic of China and the State-owned Assets Supervision and Administration Commission of the State Council regarding the number of years that an accounting firm may continuously undertake the audit work on financial statements of central state-owned enterprises, the term of service of Ernst & Young has reached the prescribed time limit. Based on the result of the tender, the Company intends to appoint PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP as the international auditor and the domestic auditor of the Company, respectively, upon the expiration of the term of service of Ernst & Young (the “**Proposed Change of Auditors**”) and will not re-appoint Ernst & Young as the auditor of the Company.

The term of service of PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP is proposed to commence from the date of the shareholders' approval at the 2022 AGM up to the date of the next annual general meeting. The Proposed Change of Auditors is subject to the approval of the shareholders at the 2022 AGM.

Ernst & Young has confirmed that there are no matters regarding the Proposed Change of Auditors that need to be brought to the attention of the shareholders of the Company as at the date of this announcement. The Company has confirmed that it is not aware of any matter regarding the Proposed Change of Auditors that should be brought to the

attention of the shareholders of the Company as at the date of this announcement.

The Board would like to take this opportunity to express its sincere gratitude to Ernst & Young for its professional services provided to the Company for the past years.

A circular containing, among other things, further details of the Proposed Change of Auditors, together with a notice of the 2022 AGM, will be dispatched to the shareholders of the Company in due course.

By order of the Board
Sinopharm Group Co. Ltd.
Yu Qingming
Chairman

Shanghai, the PRC
27 April 2023

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Ma Ping, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."*